NBIX

#642
Neurocrine Biosciences Inc
132.2500
+2.38%
Setor:
Base:
Moeda do lucro:
Faixa diária
132.2000
132.2500
Faixa anual
122.1375
160.1800
Mudança diária
+2.38%
Mudança mensal
-0.57%
Mudança em 6 meses
-8.79%
Mudança anual
-8.79%
Fechamento anterior
129.1750
Open
132.2400
Bid
Ask
Low
132.2000
High
132.2500
Volume
182
Open full chart

Financials

Overview Relatórios Statistics Dividends
Quarterly Annual
  • Market Capitalization 13.1589 B
  • Employee 2 000
  • Founded 1992
  • CEO Kevin C. Gorman
  • Website www.neurocrine.com
  • Headquarter Delaware, United States
  • FIGI BBG000GJS7C1
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
30.37
Price to sales ratio
5.08
Dividends per share
—
Dividend yield %
—

Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia. The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.

Notícias